How many investments has PureTech Health made?

PureTech Health has 11 tracked investments, 5 of which have exited, including 2 dated in the last 24 months.

What sectors does PureTech Health focus on?

PureTech Health focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is PureTech Health located?

PureTech Health is headquartered in Boston, US.

Does PureTech Health lead rounds?

PureTech Health typically participates in rounds rather than leading them.

Who does PureTech Health co-invest with?

PureTech Health most often shares deals with Sofinnova Ventures, ARCH Venture Partners, Foresite Capital, among 5 tracked co-investors.

PureTech Health

Venture studio

Boston · 15 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into PureTech Health

6,975 people in our graph share verified history with the PureTech Health team — schools, employers, funds. One of them is your warm intro.

Anthony Philippakisunlockedknows Raju Kucherlapati · together at Brigham and Women's Hospital (overlapped)

×4knows the team · via Harvard Medical School

×3knows the team · via Georgetown

×3knows the team · via Brigham and Women's Hospital

knows the team · via KPMG Luxembourg

✨ Fox Verdict

Investment thesis

PureTech Health builds and develops novel medicines by identifying patient needs where an existing therapeutic approach has demonstrated human efficacy but is held back by limitations such as off-target effects, low bioavailability, or poor tolerability. Its R&D model rests on three principles: validated efficacy, clear patient benefit, and an efficient, de-risked path to new classes of medicine. Programs are advanced through Founded Entities, exemplified by KarXT (Cobenfy) for schizophrenia, developed in Karuna Therapeutics and later acquired by Bristol Myers Squibb. Other programs include deupirfenidone for idiopathic pulmonary fibrosis and GlyphAllo, an oral allopregnanolone prodrug using its Glyph technology for mental health indications.

Invests inBiotech Digital Health Healthtech Medical Devices Boston Europe North America United States

Source: firm website, verified Sep 26, 2026.

What founders say

No founder feedback on PureTech Health yet.

Leave your own feedback

Boston, US

Leads rounds

Follows

Last 12 months

1 investment

Tracked investments

IPOs

Acquisitions

Team · 15 people

from the firm's website & curated

Eric Elenko· Co-founder & President

Co-founder and president of PureTech who led development of several programs including three FDA-approved products, and co-founded Seaport Therapeutics. Formerly a McKinsey consultant; holds a PhD in biomedical sciences from UC San Diego.

Robert Langer· Co-Founder & Non-Executive Director

Co-founder and board member since PureTech's founding, and the David H. Koch Institute Professor at MIT. A prolific inventor with 1,350+ patents and numerous top scientific awards.

Allison Mead Talbot· Senior Vice President, Communications· Boston, Massachusetts, United Statesin

SVP of communications directing corporate, brand, and internal communications plus investor and media relations, joining PureTech in 2016 after leadership roles at PR agencies TogoRun and Feinstein Kean Healthcare.

Charles (Chip) Sherwood· Chief Operating Officer & General Counsel

COO and general counsel leading PureTech's strategic, operational and legal functions since 2021, previously VP Corporate Legal Counsel at Anika Therapeutics. Holds a JD from Vanderbilt and is admitted to the Massachusetts Bar.

H. Robert Horvitz· Board Observer, R&D Committee Chair

Board observer and R&D Committee chair, Nobel laureate in Physiology or Medicine, and David H. Koch Professor of Biology at MIT. Co-founder of multiple life science companies including Epizyme.

John LaMattina· Independent Non-Executive Director· Stonington, Connecticut, United Statesin

Independent non-executive director since 2009 and former president of Pfizer Global Research and Development after a 30-year Pfizer career. Serves on several biotech boards and holds a PhD in organic chemistry.

Kiran Mazumdar-Shaw· Independent Non-Executive Director

Independent non-executive director and pioneering biotech entrepreneur who founded Biocon. Serves on boards including Infosys and Narayana Health and holds numerous civilian honors.

Michael Inbar· Chief Accounting Officer

Chief accounting officer overseeing accounting, compliance and finance operations, joining PureTech in 2023 after serving as CFO of Acronis and interim CFO of Wallarm. Has over 20 years of finance experience, including 11 years in public accounting at EY.

Michele Holcomb· Non-Executive Director, Audit Committee Member

Independent non-executive director with 30+ years in healthcare, previously EVP and Chief Strategy Officer at Cardinal Health and COO of Global R&D at Teva. Holds a PhD in chemistry from UC Berkeley.

Robert Lyne· Chief Executive Officer· Greater London, England, United Kingdomin

CEO and board member of PureTech, previously CEO of Arix Bioscience plc, with over a decade of leadership at London-listed life science companies and involvement in 80+ venture financings. Began his career as a lawyer at Bird & Bird before moving to Touchstone Innovations.

Sharon Barber-Lui· Interim Chair of the Board of Directors, Audit Committee Member· Stonington, Connecticut, United Statesin

Interim board chair and audit committee member, currently CFO North America at Teva Pharmaceuticals, with over two decades of finance leadership at Merck.

Fadi Selwan· Senior Vice President, Communications· Paris, Île-de-France, Francein

Fadi Selwan is Partner, Deputy Chief Executive Officer, and ExCom Member at Meridiam, where he oversees portfolio management, human capital, and sustainability functions globally. He joined the VINCI Group in 2007 as Development Director of VINCI Concessions, later serving as Executive Vice President from 2012 to 2019, Chairman of VINCI Highways from 2014 to 2019, and Operational Director of the Americas and LNG Reservoir Businesses Division of VINCI Construction Grands Projets from 2019, following earlier roles at the Eiffage Group. He holds an engineering degree from the École Nationale des Ponts et Chaussées in France and a Master of Science in Civil Engineering from the Massachusetts Institute of Technology.

Nishtha Pandit· Interim Chairperson of the Boardin

Raju Kucherlapati· Member, BOD· Weston, Floridain

Raju Kucherlapati is a Professor of Genetics at Harvard Medical School. He earned his PhD from the University of Illinois Urbana-Champaign and completed postdoctoral training at Yale University, following degrees earned in India. He was elected to the National Academy of Medicine and served on the Presidential Commission for the Study of Bioethical Issues from 2009 to 2017.

Zakaria Fechtali· Chief Executive Officer· Francein

Founder mafia

The PureTech Health mafia →

11 people who came through PureTech Health went on to found or lead other companies.

David SteinbergCo-Founder and Chief Innovation OfficerFounded Restorbio +4 Michael ChenHead of InnovationFounded Sondehealth +1 Isaac StonerSenior DirectorFounded Octagon Therapeutics +1 Aleks Radovic-MorenoSenior Vice PresidentFounded Vor Biopharma Raju KucherlapatiMember, BODFounded KEW Group Daphne ZoharFounder, CEO & Board MemberFounded Seaport Therapeutics Bernat OlleVenture PartnerFounded Vedanta Biosciences Harry LeiderSenior AdvisorFounded Zeo ScientifiX Michael McKeownDirector of Preclinical ResearchFounded Bullseye Biosciences David LucchinoCEOFounded Frequency Therapeutics James HarperEntrepreneur-in-ResidenceFounded Sondehealth

What they invest in

from 7 of 11 portfolio companies

Biotech ×6Healthtech ×5Digital Health ×1Medical Devices ×1Mental Health ×1Wellness & Fitness ×1

HQs:United States×5

Investments · 11 tracked

founders shown can be your intro path

By year:2026 · 1 2024 · 1 2022 · 1 2020 · 1 2019 · 1 2018 · 16 dated

Adicet Bioadicetbio.comNASDAQ: ACET

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in

Board Jonathan Silverstein(Director)in Carl Gordon(Director)inFlorent Gros(Director)

Co-investorsForesite Capital OrbiMed Pontifax Venture Capital Quan Capital aMoon Novartis Venture Fund

Seaport Therapeuticsseaporttx.com in 𝕏NASDAQ: SPTXOct 2024

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

Daphne Zohar(Founder, CEO & Board Member)in Steven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)in Lana Gladstein(Executive Officer)in Antony Loebel(Executive Officer)in

Co-investorsARCH Venture Partners Foresite Capital HAWKTAIL Sofinnova Ventures CPP Investments General Atlantic +3 more

Vor Biopharmavorbio.comNASDAQ: VORJun 2020

Vor Biopharma is a biopharmaceutical company.

BiotechCambridge, US

Nathan Jorgensen(Executive Officer)Amy Mendel(Executive Officer)Robert Ang(Executive Officer, Director)Jean-Paul Kress(President, Chief Executive Officer and Chairman of the Board)in

Board Kush Parmar(Director)inJoshua Resnick(Director)

Co-investors5AM Ventures OUP (Osage University Partners)RA Capital

Celea Therapeuticsceleatx.com inJul 2026 · $180M

Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.

BiotechHealthtechMedical Devices

Co-investorsRA Capital Leaps by Bayer

Chimera Bioengineeringchimera.bio inApr 2022 · $8M

Chimera develops engineered cell therapies for cancer that produce therapeutic proteins only upon encountering tumor cells, using natural biological control mechanisms to improve safety and efficacy.

BiotechHealthtech

Co-investorsSand Hill Angels ShangBay Capital LLC

Gelesisgelesis.com inMar 2018 · $30M

Gelesis develops an oral superabsorbent hydrogel platform (OHS) built from naturally derived materials that works locally in the GI tract to influence satiety signals and support metabolic health.

BiotechDigital HealthHealthtechWellness & FitnessBoston, US

Yishai Zohar(Director, President, and Chief Executive Officer)inElliot Maltz(Treasurer)in

BoardJohn LaMattina(Director)Elon Boms(Director)inMeghan Fitzgerald(Director)Robert Forrester(Director)in

Co-investorsLaunchCapital Capstar Ventures Invesco OrbiMed Vitruvian Partners

Karunatxkarunatx.comApr 2019Acquired

Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.

Co-investorsARCH Venture Partners Pivotal Life Sciences Sofinnova Ventures Alexandria Wellcome Trust

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Akili Interactive LabsGallop OncologyKarunaKaruna Therapeutics

Exits · 5

3 IPOs · 2 acquisitions · showing 3

Adicet BioNASDAQ: ACETSeaport TherapeuticsNASDAQ: SPTXVor BiopharmaNASDAQ: VOR

Portfolio news

latest coverage across their companies

Celea Therapeutics Raises $180M in Financing

Celea Therapeutics · finsmes.com · Jul 2, 2026

IPO stake values · per SEC filings · 2

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Adicet Bio	35.2%	$15.00	Jan 2018	$143.5M
Vor Biopharma	9.0%	$18.00	Feb 2021	$57.7M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has PureTech Health made?: PureTech Health has 11 tracked investments, 5 of which have exited, including 2 dated in the last 24 months.
What sectors does PureTech Health focus on?: PureTech Health focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is PureTech Health located?: PureTech Health is headquartered in Boston, US.
Does PureTech Health lead rounds?: PureTech Health typically participates in rounds rather than leading them.
Who does PureTech Health co-invest with?: PureTech Health most often shares deals with Sofinnova Ventures, ARCH Venture Partners, Foresite Capital, among 5 tracked co-investors.

Similar investors

Investinor

Investinor AS is a Norwegian investment company that partners with founders, entrepreneurs and other investors to help selected promising companies become world-leading.

Third Rock Ventures

Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.

$100K – $5M

Arboretum Ventures

Arboretum Ventures is a Midwest-based venture capital firm focused on the healthcare industry, investing in early-stage companies across medical devices, life science tools and diagnostics, tech-enabled care delivery, and pharma adjacencies.

$5M – $15M

Illumina Ventures

Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.

Life Sciences Greenhouse Investments

Life Sciences Greenhouse Investments (LSGI) is an evergreen venture fund that provides early-stage capital and operational support to Pennsylvania life science companies working on drug discovery, diagnostics, devices, and healthcare IT solutions.

$250K – $500K